选择语言

Human B7-2 / CD86 Protein, His Tag (MALS verified)

用户评价
货号-规格
价格
Qty.
CD6-H5223-100ug
¥2940.00
CD6-H5223-1mg (250ug X 4)
¥17850.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

  • 表达区间及表达系统(Source)

    Human B7-2, His Tag (CD6-H5223) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261).

    Predicted N-terminus: Leu 26

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    B7-2 Structure

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 26.2 kDa. The protein migrates as 40-63 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 偶联(Conjugate)

    Unconjugated

  • 内毒素(Endotoxin)

    Less than 1.0 EU per μg by the LAL method.

  • 纯度(Purity)

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • 电泳(SDS-PAGE)

    B7-2 SDS-PAGE

    Human B7-2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    B7-2 SEC-MALS

    The purity of Human B7-2, His Tag (Cat. No. CD6-H5223) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     B7-2 ELISA

    Immobilized Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human B7-2, His Tag (Cat. No. CD6-H5223) with a linear range of 0.01-2.5 μg/mL (QC tested).

    Protocol
  • 活性(Bioactivity)-BLI

     B7-2 BLI

    Loaded Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on Protein A Biosensor, can bind Human B7-2, His Tag (Cat. No. CD6-H5223) with an affinity constant of 6.8 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  B7-2 BLI

    Loaded Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) on Protein A Biosensor, can bind Human B7-2, His Tag (Cat. No. CD6-H5223) with an affinity constant of 1.9 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

前沿进展

 
药物研发进展
  • 英文全称:

    Cluster of differentiation 86

  • 中文全称:

    分化群86

  • 种类:

  • 上市药物数量:

    2 详情

  • 临床药物数量:

    5 详情

  • 最高研发阶段:

    批准上市

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍